The neatly dressed crowd that gathered in the Port of Los Angeles board room to talk tech, renewable energy and the environment was a far cry from the burly, rugged males you’d expect working the docks in a Disney movie. These scientists and inventors were flexing brains.
More than 100 people gathered to watch the PortTech Pitch finals, a techie–meets-roustabout melding at which nine companies pitched ideas to resolve pressing issues in Los Angeles, Long Beach and other ports, everything from saving lives in the mounting battle against bacteria to improving military security to finally coming up with a superior solar shower.
Velox Biosystems, the grand prize winner, created technology that monitors and quickly tests bacteria in water. Treatment plants release contaminated water accidentally but generally don’t find out about it until the water makes it into reservoirs or the broader environment. Velox’s system is intended to alert treatment centers to such tainted water before it reaches the public.
Each company founder or CEO got eight minutes to argue his or her case, then eight minutes to field questions from a panel of judges assembled by nonprofit PortTech. The judges included investors, venture capitalists and environmental specialists from the local ports.
In recent years, new strains of bacteria have emerged that resist even the most powerful antibiotics. Each year, these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect more than 2 million people nationwide, and kill at least 23,000. Despite the urgent need for new treatments, scientists have discovered very few new classes of antibiotics in the past decade.
MIT engineers have now turned a powerful new weapon on these superbugs. Using a gene-editing system that can disable any target gene, they have shown that they can selectively kill bacteria carrying harmful genes that confer antibiotic resistance or cause disease.
Led by Timothy Lu, an associate professor of biological engineering and electrical engineering and computer science, the researchers described their findings in the Sept. 21 issue of Nature Biotechnology. Last month, Lu’s lab reported a different approach to combating resistant bacteria by identifying combinations of genes that work together to make bacteria more susceptible to antibiotics.
Lu hopes that both technologies will lead to new drugs to help fight the growing crisis posed by drug-resistant bacteria.
“This is a pretty crucial moment when there are fewer and fewer new antibiotics available, but more and more antibiotic resistance evolving,” he says. “We’ve been interested in finding new ways to combat antibiotic resistance, and these papers offer two different strategies for doing that.”
Cutting out resistance
Most antibiotics work by interfering with crucial functions such as cell division or protein synthesis. However, some bacteria, including the formidable MRSA (methicillin-resistant Staphylococcus aureus) and CRE (carbapenem-resistant Enterobacteriaceae) organisms, have evolved to become virtually untreatable with existing drugs.
In the new Nature Biotechnology study, graduate students Robert Citorik and Mark Mimee worked with Lu to target specific genes that allow bacteria to survive antibiotic treatment. The CRISPR genome-editing system presented the perfect strategy to go after those genes.
CRISPR, originally discovered by biologists studying the bacterial immune system, involves a set of proteins that bacteria use to defend themselves against bacteriophages (viruses that infect bacteria). One of these proteins, a DNA-cutting enzyme called Cas9, binds to short RNA guide strands that target specific sequences, telling Cas9 where to make its cuts.
Lu and colleagues decided to turn bacteria’s own weapons against them. They designed their RNA guide strands to target genes for antibiotic resistance, including the enzyme NDM-1, which allows bacteria to resist a broad range of beta-lactam antibiotics, including carbapenems. The genes encoding NDM-1 and other antibiotic resistance factors are usually carried on plasmids — circular strands of DNA separate from the bacterial genome — making it easier for them to spread through populations.
When the researchers turned the CRISPR system against NDM-1, they were able to specifically kill more than 99 percent of NDM-1-carrying bacteria, while antibiotics to which the bacteria were resistant did not induce any significant killing. They also successfully targeted another antibiotic resistance gene encoding SHV-18, a mutation in the bacterial chromosome providing resistance to quinolone antibiotics, and a virulence factor in enterohemorrhagic E. coli.
In addition, the researchers showed that the CRISPR system could be used to selectively remove specific bacteria from diverse bacterial communities based on their genetic signatures, thus opening up the potential for “microbiome editing” beyond antimicrobial applications.
To get the CRISPR components into bacteria, the researchers created two delivery vehicles — engineered bacteria that carry CRISPR genes on plasmids, and bacteriophage particles that bind to the bacteria and inject the genes. Both of these carriers successfully spread the CRISPR genes through the population of drug-resistant bacteria. Delivery of the CRISPR system into waxworm larvae infected with a harmful form of E. coli resulted in increased survival of the larvae.
The researchers are now testing this approach in mice, and they envision that eventually the technology could be adapted to deliver the CRISPR components to treat infections or remove other unwanted bacteria in human patients.
“This work represents a very interesting genetic method for killing antibiotic-resistant bacteria in a directed fashion, which in principle could help to combat the spread of antibiotic resistance fueled by excessive broad-spectrum treatment,” says Ahmad Khalil, an assistant professor of biomedical engineering at Boston University who was not part of the research team.
High-speed genetic screens
Another tool Lu has developed to fight antibiotic resistance is a technology called CombiGEM. This system, described in the Proceedings of the National Academy of Sciences the week of Aug. 11, allows scientists to rapidly and systematically search for genetic combinations that sensitize bacteria to different antibiotics.
To test the system, Lu and his graduate student, Allen Cheng, created a library of 34,000 pairs of bacterial genes. All of these genes code for transcription factors, which are proteins that control the expression of other genes. Each gene pair is contained on a single piece of DNA that also includes a six-base-pair barcode for each gene. These barcodes allow the researchers to rapidly identify the genes in each pair without having to sequence the entire strand of DNA.
“You can take advantage of really high-throughput sequencing technologies that allow you, in a single shot, to assess millions of genetic combinations simultaneously and pick out the ones that are successful,” Lu says.
The researchers then delivered the gene pairs into drug-resistant bacteria and treated them with different antibiotics. For each antibiotic, they identified gene combinations that enhanced the killing of target bacteria by 10,000- to 1,000,000-fold. The researchers are now investigating how these genes exert their effects.
“This platform allows you to discover the combinations that are really interesting, but it doesn’t necessarily tell you why they work well,” Lu says. “This is a high-throughput technology for uncovering genetic combinations that look really interesting, and then you have to go downstream and figure out the mechanisms.”
Once scientists understand how these genes influence antibiotic resistance, they could try to design new drugs that mimic the effects, Lu says. It is also possible that the genes themselves could be used as a treatment, if researchers can find a safe and effective way to deliver them.
CombiGEM also enables the generation of combinations of three or four genes in a more powerful way than previously existing methods. “We’re excited about the application of CombiGEM to probe complex multifactorial phenotypes, such as stem cell differentiation, cancer biology, and synthetic circuits,” Lu says.
The research was funded by the National Institutes of Health, the Defense Threat Reduction Agency, the U.S. Army Research Laboratory, the U.S. Army Research Office, the Office of Naval Research, and the Ellison Medical Foundation.
The rise in antibiotic-resistant bacteria could lead to a future full of untreatable infections, experts have warned us for years.
Now the Obama administration is stepping up its efforts to combat the rising problem of antibiotic resistance. The President signed an executive order Thursday establishing a new inter-agency task force charged with developing a national strategy to combat antibiotic-resistant bacteria.
Dr. John Holdren, director of the White House Office of Science and Technology Policy and assistant to the President, said the problem is a serious challenge to public health and national security.
“We are clearly in a fight against … bacteria where no permanent treatment is possible.”
The task force will be co-chaired by the secretaries of Health & Human Services, the Department of Defense and the Department of Agriculture. The task force must submit its national action plan to the President by February 15, 2015.
The order also established a Presidential Advisory Council made up of nongovernmental experts who will provide advice and recommendations to strengthen surveillance of infections, research new treatments and develop alternatives to antibiotics for use in agriculture.
On Thursday, the administration released “National Strategy on Combating Antibiotic-Resistant Bacteria,” a five-year plan to prevent and contain outbreaks and develop the next generation of tests, antibiotics and vaccines.
The President’s Council of Advisers on Science and Technology — known as PCAST — also released a report on combating antibiotic resistance.
There are three main components to the report: improve surveillance of antibiotic-resistant bacteria and stop outbreaks; increase the life of current antibiotics and develop new ones, as well as promote research accelerating clinical trials; and increase economic incentives to develop new antibiotics.
In fact, a $20 million prize will be given to spur development of tests health care professionals can use to identify highly resistant bacterial infections.
“What’s new here is there is a highly federal focus that’s highly coordinated,” said Dr. Eric Lander, co-chair of PCAST. “We are endorsing a variety of specific goals in order to get our arms around this problem. If we’re producing antibiotics at a greater rate than we’re losing them, then we win in the long run.”
Each year 23,000 deaths and 2 million illnesses are linked to antibiotic-resistant infections, according to the Centers for Disease Control and Prevention. The agency estimates the impact to the economy is as high as $20 billion in direct health care costs.
Last year, for the first time, the CDC classified drug-resistant superbugs by how dangerous they were. They were ranked “urgent,” “serious” and “concerning” based on how many people get sick, the number of hospitalizations and how many deaths were attributed to them.
“If we can target our efforts more effectively,” CDC Director Dr. Tom Frieden said, “we can help doctors use antibiotics more wisely.”
Dr. Jesse Goodman, director of the Center on Medical Product Access, Safety and Stewardship at Georgetown University Medical Center, says antibiotic resistance is one of the most pressing global public health threats.
Until earlier this year, Goodman was the Food and Drug Administration’s Chief Scientist. He co-chaired the first U.S. Task Force to Combat Antimicrobial Resistance, which released the first action plan in 2000. He says investment in new treatments must be paired with the sensible use of new and existing antibiotics.
“Success will require a sea change. Doctors, farmers and agribusiness, health systems and the public all need to think totally differently about antibiotics,” Goodman said. “They are precious resources and we must reduce their inappropriate use. Better diagnosis and stronger infection control practices can make a big difference right now.”